PHILADELPHIA—Patients with rheumatic diseases often mount an adequate immune response after receiving COVID-19 vaccinations, but that is not always the case, and certain medications make patients more prone to having an insufficient response, said Judith James, MD, PhD, chair, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, at an ACR Convergence…
What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases
PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
COVID-19: Strategies to Protect Adult & Pediatric Patients
An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.
Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease
PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…
COVID-19 Vaccinations in Immune-Compromised Patients
A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
The Rheumatologist Honored with Grand Award for Publication Excellence
We are honored to announce that The Rheumatologist has received a Grand Award for publication excellence from APEX 2022 for COVID-19: A Special Report, a supplement that mailed with the February 2021 issue of the magazine. The Annual Awards for Publication Excellence (APEX) are based on excellence in graphic design, editorial content and the ability…
Case Report: Dermato-Neuro Syndrome Recurrence after a Viral Infection
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…
Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients
In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…
Recent Research: Study Summaries from Arthritis Care & Research
Lupus & Perinatal Outcomes Adverse perinatal outcomes before & after diagnosis with systemic lupus erythematosus among African American Women By Meghan Angley, PhD, & S. Sam Lim, MD Why was this study done? Previous studies have suggested that women with systemic lupus erythematosus (SLE) may experience adverse perinatal outcomes, including preterm and small-for-gestational-age birth, in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 27
- Next Page »